SCHEMBL6858201

SCHEMBL6858201

CN1C(=N)NCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21817836 0.98
SCHEMBL17918987 0.76
SCHEMBL377630 0.76
SCHEMBL17982475 0.72
SCHEMBL22416283 0.70 BRPF1 (0.44)
SCHEMBL28159 0.70
SCHEMBL11987580 0.70
SCHEMBL83965 0.67
SCHEMBL12260101 0.66 CA12 (0.52)
SCHEMBL9961922 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014019855-A1 METHOD FOR PREPARING CREATINE FATTY ESTERS, CREATINE FATTY ESTERS THUS PREPARED AND USES THEREOF Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2014-02-06 WO disclosed
WO-2011015646-A2 FURAN-IMIDAZOLONE DERIVATIVES, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS NOSCIRA, S.A. (ES) 2011-02-10 WO disclosed
EP-2281824-A1 Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders NOSCIRA, S.A. (ES) 2011-02-09 EP disclosed
US-7763609-B2 Use in treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, inhibitors of Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes; 4-imidazolidinone, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-5-cyclopropyl-2-imino-3-(2,2,2-trifluoroethyl)-, for example SCHERING CORPORATION (US) 2010-07-27 US disclosed
US-20080200445-A1 Use in treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, inhibitors of Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes; 4-imidazolidinone, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-5-cyclopropyl-2-imino-3-(2,2,2-trifluoroethyl)-, for example SCHERING CORPORATION & PHARMACOPEIA DRUG DISCOVERY, INC. 2008-08-21 US disclosed
EP-1355616-A2 REVITALISING ACTIVE COMPLEX FOR THE SKIN Coty B.V. (NL) 2003-10-29 EP disclosed
WO-2002060394-A2 REVITALISING ACTIVE COMPLEX FOR THE SKIN COTY B.V. (NL) 2002-08-08 WO disclosed